Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study

Table 2

Perception of treatment satisfaction and most commonly reported symptom (Sx) changes in responders and nonresponders during placebo and pregabalin conditions.

(a)

	Responders ()			Nonresponders ()
	Pregabalin	Placebo	Preg versus Plac	Pregabalin	Placebo	Preg versus Plac
Satisfaction	2.5 ± 0.37	0.3 ± 0.25	<0.001	0.1 ± 0.14	1.6 ± 0.57	0.039
# Sx improved	7.2 ± 1.35	1.3 ± 0.91	<0.001	1.0 ± 0.53	4.3 ± 2.11	0.106
# Sx worse	1.8 ± 0.52	6.4 ± 1.38	0.002	3.7 ± 0.99	1.9 ± 0.63	0.064

(b)

	⁢Responders ()		⁢Nonresponders ()
	Improved	Worse	Improved	Worse
Placebo condition
≥50%	0	Sleep (7); Physical fatigue (7); Ability to do chores (7); Total energy (6); Muscle pain (6); Mental fog (6)	0	0
25–49%	0	Need for bed rest (5); Headaches (4); PEM (3); Sensitivity to noise (3); Ability to relax (3)	Mental fog (3); Pain (3); Ability to do chores (2); Sleep (2); Need for bed rest (2); Anxiety (2); Depression (2); Back pain (2); Ability to relax (2); Sensitivity to noise (2)	Sleep (2); Physical fatigue (2); Light-headedness (2)
Pregabalin condition
≥50%	Muscle pain (10); PEM (8); Ability to do chores (8); Total energy (7); Sleep (7)	0	0	Mental Fog (5)
25–49%	Physical fatigue (5); Mental fog (4); Back pain (4); Headaches (4); Depression (4); Ability to relax (4); Need for bed rest (4)	Weight gain (3); Light-headedness (3)	Pain (2); Sleep (2); Total energy (2)	Light-headedness (3); Anxiety (2); Depression (2); Headaches (2); Blurred vision (2)

Satisfaction was rated on a 0-to-4 scale, where 0 means “not at all” and 4 means “very much.”
# Sx: number of symptoms reported by participants; values are mean ± SE.
≥50% refers to symptoms that were reported in at least 50% of the group.
25–49% refers to symptoms that were reported in 25–49% of the group.
PEM: postexertional malaise.